A Randomized, Open-label, Single-dose, Two-way Crossover, Phase 1 Trial to Evaluate Bioequivalence of LCB01-0371(Batch no. 1650006) andLCB01-0371(Batch no. 3183817R) in Healthy Adult Subjects
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Delpazolid (Primary)
- Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Tuberculosis; Vancomycin-resistant enterococcal infections
- Focus Pharmacokinetics
- Sponsors LegoChem Biosciences
- 30 Jun 2021 New trial record